6505--Cyclobenzaprine Tablets (VA-25-00015093)

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Cyclobenzaprine HCL 10mg tablets to be distributed through VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The solicitation (36E79725R0009) seeks to establish a requirements contract for multiple bottle sizes including 30, 60, 90, 180, 270, and either 500 or 1000 tablet configurations. Key contract requirements include FDA compliance, current Good Manufacturing Practices (cGMP) status, bar coding requirements, and Drug Supply Chain Security Act compliance. The solicitation is unrestricted but includes a HUBZone price evaluation preference, meaning offerors will be evaluated based on their pricing, compliance with regulations, and potential price advantages for HUBZone-certified businesses. Offers are due by January 22, 2025, at 2:30 PM CST, with vendors required to submit pricing for the base year and all four option years to be considered for award.

The contract will be awarded to a single vendor in the aggregate for all line items, with authorized users including VA facilities, DoD PPV Program participants, Indian Health Service facilities, Bureau of Prisons facilities, the Captain James A. Lovell Federal Health Care Center, and Option 2 State Veteran Homes. Estimated annual quantities range from 5,388 bottles (270-count) to 252,863 bottles (90-count), indicating a significant procurement volume. The contract structure includes a base year with four additional one-year option periods, providing potential long-term stability for the selected vendor. A 0.5% Cost Recovery Fee must be included in the pricing, which is a standard requirement for this type of pharmaceutical contract. While specific award values are not explicitly stated, the high-volume requirements and multi-year contract structure suggest a substantial potential contract value for the successful offeror.